Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.69 |
| ▸ | PRKCG | P05129 | 5/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.69 |
| ▸ | PRKCB | P05771 | 4/20 | 0.69 |
| ▸ | PRKCH | P24723 | 4/20 | 0.69 |
| ▸ | PRKCI | P41743 | 4/20 | 0.69 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.69 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.69 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.69 |
| ▸ | USP2 | O75604 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phorbol SCHEMBL20582541 | 1.00 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL10620832 | 1.00 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27616694 | 1.00 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL1893791 | 1.00 | PRKCA (0.69) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27579226 | 0.96 | PRKCA (0.67) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL21462215 | 0.92 | PRKCA (0.66) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL5904049 | 0.92 | PRKCA (0.60) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL27299282 | 0.90 | PRKCA (0.63) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL7615331 | 0.90 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH | |
| Phorbol SCHEMBL64353 | 0.90 | PRKCA (0.62) | PRKCAPRKCGPRKD3PRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1903 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119931934-A | High-purity peripheral blood source tool B lymphocyte culture system and method | 复旦大学附属中山医院 | 2025-05-06 | — | — | CN | claimed |
| US-20240301092-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. | 2024-09-12 | — | — | US | claimed |
| CN-117904045-A | High-purity peripheral blood source tool B lymphocyte culture system and method | 复旦大学附属中山医院 | 2024-04-19 | — | — | CN | claimed |
| WO-2023278631-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. (US) | 2023-01-05 | — | — | WO | claimed |
| US-20220305049-A1 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. | 2022-09-29 | — | — | US | claimed |
| EP-4021461-A1 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | Tega Therapeutics, Inc. (US) | 2022-07-06 | — | — | EP | claimed |
| CN-113686830-B | Batch semi-channel function level detection method based on fluorescent dye uptake | 中国环境科学研究院 | 2022-05-20 | — | — | CN | claimed |
| CN-113686830-A | Batch semi-channel function level detection method based on fluorescent dye uptake | 中国环境科学研究院 | 2021-11-23 | — | — | CN | claimed |
| WO-2021041711-A1 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | TEGA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | WO | claimed |
| US-20200338125-A1 | METHOD FOR EXPANSION OF LYMPHOCYTES | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD (CH) | 2020-10-29 | — | — | US | claimed |
| US-20020160415-A1 | Methods, pharmaceutical formulations and kits for identification of subjects at risk for cancer and for the prevention of cancer in at- risk subjects | ENDACEA, INC. | 2002-10-31 | — | — | US | claimed |
| WO-2000070341-A9 | METHODS, PHARMACEUTICAL FORMULATIONS AND KITS FOR IDENTIFICATION OF SUBJECTS AT RISK FOR CANCER | LINK TECHNOLOGY INC (US) | 2002-04-18 | — | — | WO | claimed |
| EP-1180239-A2 | METHODS, PHARMACEUTICAL FORMULATIONS AND KITS FOR IDENTIFICATION OF SUBJECTS AT RISK FOR CANCER | Link Technology, Inc. (US) | 2002-02-20 | — | — | EP | claimed |
| EP-1043928-A4 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | LINK TECHNOLOGY INC (US) | 2001-01-17 | — | — | EP | claimed |
| US-6159701-A | Method and compositions for treating and diagnosing tumors using adenosine receptor activated cells | LINK TECHNOLOGY INCORPORATED (US) | 2000-12-12 | — | — | US | claimed |
| EP-1054954-A1 | DEVELOPMENT OF REGULATORY CELLS AS A MEANS FOR TREATING AUTOIMMUNE DISEASE | HEMOSOL INC. (CA) | 2000-11-29 | — | — | EP | claimed |
| WO-2000070341-A2 | METHODS, PHARMACEUTICAL FORMULATIONS AND KITS FOR IDENTIFICATION OF SUBJECTS AT RISK FOR CANCER | LINK TECHNOLOGY, INC. (US) | 2000-11-23 | — | — | WO | claimed |
| EP-1043928-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | Link Technology, Inc. (US) | 2000-10-18 | — | — | EP | claimed |
| WO-1999038953-A1 | DEVELOPMENT OF REGULATORY CELLS AS A MEANS FOR TREATING AUTOIMMUNE DISEASE | HEMOSOL INC. (CA) | 1999-08-05 | — | — | WO | claimed |
| WO-1998019541-A1 | METHODS AND COMPOSITIONS FOR TREATING AND DIAGNOSING TUMORS USING ADENOSINE RECEPTOR ACTIVATED CELLS | LINK TECHNOLOGY, INC. (US) | 1998-05-14 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240301092-A1 | HEPARIN FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MST1, MST1R, HPSE | PRKCA 2076/4885PRKCG 2228/4885PRKD3 1834/4885 |
| US-20220305049-A1 | HEPARIN AND HEPARAN SULFATE FROM MODIFIED MST CELLS AND METHODS OF MAKING AND USING | MST1, HPSE, MST1R | PRKCA 2341/4885PRKCG 2519/4885PRKD3 1818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.